

 Early Warning System

EIB-20230984
UNIVERSALDX (IEU TI)



Quick Facts

Countries	Slovenia, Spain
Financial Institutions	European Investment Bank (EIB)
Status	Approved
Bank Risk Rating	U
Voting Date	2024-12-16
Borrower	UNIVERSAL DIAGNOSTICS SA
Sectors	Education and Health, Industry and Trade
Investment Type(s)	Loan
Investment Amount (USD)	\$ 21.03 million
Project Cost (USD)	\$ 96.76 million



Project Description

According to the Bank's website, the loan will finance the research and development (R&D) investments of the promoter, a molecular diagnostics company developing blood-based screening tests for the early detection of cancer.

The aim is to further advance the promoter's pipeline and bring the products to the medical market.

The EIB financing will support the expansion of Universal Dx's most advanced product, Signal-C® for Colorectal Cancer Screening and the development of other pipeline products: Signal-Li and Signal-Lu for Liver and Lung cancer respectively. The loan will also support Universal DX international expansion plan, including advancing a large clinical trial in the US for FDA approval and reimbursement.



Early Warning System Project Analysis

Based on the environment, climate and social (ECS) information, the review of the ECS risks and impacts and the management systems in place, the project is deemed to have low residual ECS risks and impacts.



Investment Description

- European Investment Bank (EIB)



Private Actors Description

Universal DX is a Spanish startup developing cutting-edge blood-based liquid biopsy solutions for the early detection of cancer.



Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	UNIVERSAL DIAGNOSTICS SA	Client	-



Contact Information

Contact: Maite Cordero
Email: m.corderomunoz@eib.org
Phone: +34 606 66 82 62

ACCESS TO INFORMATION

You can submit an information request for project information at: <https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm>

ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: <http://www.eib.org/complaints/form> via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check: http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: <http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces>



Bank Documents

- [Environmental and Social Data Sheet \(ESDS\) - UNIVERSALDX \(IEU TI\)](#) [Original Source]

Media

- [France: The EIB and CDC Biodiversité have signed a partnership to look into biodiversity credit plac](#)
- [Spain: EIB finances with €20 million Universal DX to develop innovative diagnostic tests for early c](#)



Other Related Projects

- EIB-20220306 THEMATIC INNOVATION (INVESTEU VD) PL